Inhibikase Therapeutics (IKT) Stock Chart & Stock Price History $1.66 -0.04 (-2.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 06/20/2025 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Inhibikase Therapeutics Stock Price Performance The Inhibikase Therapeutics (IKT) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 18.57%, with a year-to-date return of -48.92%. In the past month, the stock has decreased 6.21%, reflecting recent market activity. As of the latest close, Inhibikase Therapeutics traded at $1.66 with a market cap of $123.41 million and volume of 278,054 shares. Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-2.35%1 Month Performance-6.21%3 Month Performance-29.96%Year-To-Date Performance-48.92%1 Year Performance+18.57% IKT Stock Chart for Monday, June, 23, 2025 IKT Chart by TradingView Inhibikase Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/20/2025$1.70$1.66-2.35%$1.86$1.66278,054 shs$123.41 million06/19/2025$1.70$1.70$1.78$1.70188,985 shs$126.38 million06/18/2025$1.74$1.70-2.30%$1.78$1.70188,985 shs$126.38 million06/17/2025$1.94$1.74-10.31%$1.95$1.74226,848 shs$129.36 million06/16/2025$1.86$1.94+4.30%$1.97$1.85152,495 shs$144.22 million06/13/2025$1.91$1.86-2.62%$1.98$1.8592,001 shs$138.28 million06/12/2025$1.96$1.91-2.55%$2.03$1.9058,585 shs$141.99 million06/11/2025$2.01$1.96-2.24%$2.05$1.9495,621 shs$145.71 million06/10/2025$1.95$2.01+2.82%$2.07$1.98133,043 shs$149.06 million06/09/2025$1.96$1.95-0.51%$2.00$1.9296,548 shs$144.97 million Get the Latest News and Ratings for IKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 06/06/2025$1.96$1.96$2.01$1.91185,188 shs$145.71 million06/05/2025$1.98$1.96-1.01%$2.03$1.93111,263 shs$145.71 million06/04/2025$2.03$1.98-2.46%$2.05$1.9893,068 shs$147.20 million06/03/2025$2.05$2.03-0.98%$2.13$2.0295,042 shs$150.91 million06/02/2025$2.03$2.05+0.99%$2.08$2.0057,410 shs$152.40 million05/30/2025$2.08$2.03-2.40%$2.16$1.9567,720 shs$150.91 million05/29/2025$2.04$2.08+1.96%$2.13$2.0493,803 shs$154.63 million05/28/2025$1.77$2.04+15.25%$2.12$1.76168,057 shs$151.66 million05/27/2025$1.77$1.77$1.94$1.70238,102 shs$131.59 million05/26/2025$1.77$1.77$1.93$1.75148,858 shs$131.59 million05/23/2025$1.84$1.77-3.80%$1.93$1.75148,858 shs$131.59 million05/22/2025$1.97$1.84-6.60%$2.02$1.83132,122 shs$136.79 million Related Companies VECT Stock Price Chart SANA Stock Price Chart SAGE Stock Price Chart KURA Stock Price Chart RLAY Stock Price Chart VERV Stock Price Chart ALT Stock Price Chart BCYC Stock Price Chart KROS Stock Price Chart MRVI Stock Price Chart Receive IKT Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NYSE:IKT) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
